Geron Corporation [NASDAQ: GERN] surged by $0.08 during the normal trading session on Monday and reaching a high of $2.06 during the day while it closed the day at $2.05. The company report on April 12, 2023 that Geron to Present at Upcoming Investor Conferences in April.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences:.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
22nd Annual Needham Virtual Healthcare ConferenceThursday, April 20 at 10:15 a.m. ET.
Geron Corporation stock has also gained 1.49% of its value over the past 7 days. However, GERN stock has declined by -35.13% in the 3 months of the year. Over the past six months meanwhile, it has lost -12.39% and lost -15.29% year-on date.
The market cap for GERN stock reached $1.08 billion, with 381.16 million shares outstanding and 380.56 million shares in the current float. Compared to the average trading volume of 5.20M shares, GERN reached a trading volume of 5119959 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Geron Corporation [GERN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GERN shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GERN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2023. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on October 28, 2022, representing the official price target for Geron Corporation stock. Previously, the target price had yet another raise to $4, while B. Riley Securities analysts kept a Buy rating on GERN stock.
The Average True Range (ATR) for Geron Corporation is set at 0.12, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 1799.90. The Price to Book ratio for the last quarter was 9.76, with the Price to Cash per share for the same quarter was set at 0.33.
GERN stock trade performance evaluation
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.49. With this latest performance, GERN shares dropped by -22.64% in over the last four-week period, additionally sinking by -12.39% over the last 6 months – not to mention a rise of 24.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 37.30, with the RSI for the last a single of trading hit 40.57, and the three-weeks RSI is set at 37.63 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 2.5500, while it was recorded at 2.0100 for the last single week of trading, and 2.4100 for the last 200 days.
Geron Corporation [GERN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -23246.64 and a Gross Margin at -45.64. Geron Corporation’s Net Margin is presently recorded at -23808.89.
Return on Total Capital for GERN is now -87.37, given the latest momentum, and Return on Invested Capital for the company is -96.40. Return on Equity for this stock declined to -137.49, with Return on Assets sitting at -68.12. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 69.69. Additionally, GERN Total Debt to Total Capital is recorded at 41.07, with Total Debt to Total Assets ending up at 29.26. Long-Term Debt to Equity for the company is recorded at 42.35, with the Long-Term Debt to Total Capital now at 24.96.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,326,178 per employee. Receivables Turnover for the company is 0.24 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Earnings per share (EPS) analysis for Geron Corporation [GERN] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
Geron Corporation [GERN]: Insider Ownership positions
There are presently around $412 million, or 50.50% of GERN stock, in the hands of institutional investors. The top three institutional holders of GERN stocks are: BLACKROCK INC. with ownership of 27,261,135, which is approximately 2.421% of the company’s market cap and around 0.10% of the total institutional ownership; STATE STREET CORP, holding 19,712,189 shares of the stock with an approximate value of $38.83 million in GERN stocks shares; and VIVO CAPITAL, LLC, currently with $37.99 million in GERN stock with ownership of nearly 26.544% of the company’s market capitalization.
Positions in Geron Corporation stocks held by institutional investors increased at the end of Monday and at the time of the Monday reporting period, where 90 institutional holders increased their position in Geron Corporation [NASDAQ:GERN] by around 45,245,697 shares. Additionally, 72 investors decreased positions by around 25,963,881 shares, while 45 investors held positions by with 137,903,912 shares. The mentioned changes placed institutional holdings at 209,113,490 shares, according to the latest SEC report filing. GERN stock had 25 new institutional investments in for a total of 17,478,178 shares, while 26 institutional investors sold positions of 3,610,767 shares during the same period.